Financials

News Ideas Technicals Forecast

LUCD fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

LUCD does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company